Top

Published in:

01-04-2019 | Brief Report

Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T

Authors: Laura Duran-Lozano, Gemma Montalban, Sandra Bonache, Alejandro Moles-Fernández, Anna Tenés, Marta Castroviejo-Bermejo, Estela Carrasco, Adrià López-Fernández, Sara Torres-Esquius, Neus Gadea, Neda Stjepanovic, Judith Balmaña, Sara Gutiérrez-Enríquez, Orland Diez

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

Disruption of splicing motifs by genetic variants can affect the correct generation of mature mRNA molecules leading to aberrant transcripts. In some cases, variants may alter the physiological transcription profile composed of several transcripts, and an accurate in vitro evaluation is crucial to establish their pathogenicity. In this study, we have characterized a novel PALB2 variant c.3201+5G>T identified in a breast cancer family.

Methods

Peripheral blood RNA was analyzed in two carriers and ten controls by RT-PCR and Sanger sequencing. The splicing profile was also characterized by semi-quantitative capillary electrophoresis and quantitative PCR. RAD51 foci formation and PALB2 LOH status were evaluated in primary breast tumor samples from the carriers.

Results

PALB2 c.3201+5G>T disrupts intron 11 donor splice site and modifies the abundance of several alternative transcripts (∆11, ∆12, and ∆11,12), also present in control samples. All transcripts are predicted to encode for non-functional proteins. Semi-quantitative and quantitative analysis of PALB2 full-length transcript indicated haploinsufficiency in carriers. One tumor exhibited PALB2 LOH and RAD51 assay indicated homologous recombination deficiency in both tumors.

Conclusions

Our results support a pathogenic classification for PALB2 c.3201+5G>T, highlighting the impact of variants causing an imbalanced expression of natural RNA isoforms in cancer susceptibility.

Available only for authorised users

Scotti MM, Swanson MS (2016) RNA mis-splicing in disease. Nat Rev Genet 17:19–32. https://doi.org/10.1038/nrg.2015.3 CrossRefPubMed

Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298. https://doi.org/10.1038/nrg775 CrossRefPubMed

de la Hoya M, Soukarieh O, López-Perolio I et al (2016) Combined genetic and splicing analysis of BRCA1 c.[594-2A> C; 641A> G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet 25:2256–2268. https://doi.org/10.1093/hmg/ddw094 CrossRefPubMedPubMedCentral

Bonnet C, Krieger S, Vezain M et al (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45:438–446. https://doi.org/10.1136/jmg.2007.056895 CrossRefPubMed

Baralle D, Buratti E (2017) RNA splicing in human disease and in the clinic. Clin Sci 131:355–368. https://doi.org/10.1042/CS20160211 CrossRef

Zhang F, Ma J, Wu J et al (2009) PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr Biol 19:524–529. https://doi.org/10.1016/j.cub.2009.02.018 CrossRefPubMedPubMedCentral

Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729. https://doi.org/10.1016/j.molcel.2006.05.022 CrossRefPubMed

Park JY, Zhang F, Andreassen PR (2014) PALB2: The hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta 1846:263–275. https://doi.org/10.1016/j.bbcan.2014.06.003 CrossRefPubMedPubMedCentral

Tung N, Domchek SM, Stadler Z et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13:581–588. https://doi.org/10.1038/nrclinonc.2016.90 CrossRefPubMedPubMedCentral

10.

Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497–506. https://doi.org/10.1056/NEJMoa1400382 CrossRefPubMedPubMedCentral

11.

Pritzlaff M, Summerour P, McFarland R et al (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161:575–586. https://doi.org/10.1007/s10549-016-4085-4 CrossRefPubMed

12.

Zhen DB, Rabe KG, Gallinger S et al (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: A PACGENE study. Genet Med 17:569–577. https://doi.org/10.1038/gim.2014.153 CrossRefPubMed

13.

AlDubayan SH, Giannakis M, Moore ND et al (2018) Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet 102:401–414. https://doi.org/10.1016/j.ajhg.2018.01.018 CrossRefPubMedPubMedCentral

14.

Bonache S, Esteban I, Moles-Fernández A et al (2018) Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. J Cancer Res Clin Oncol 144:2495–2513CrossRefPubMed

15.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S et al (2018) RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 29:1203–1210. https://doi.org/10.1093/annonc/mdy099 CrossRefPubMedPubMedCentral

16.

Castroviejo‐Bermejo M, Cruz C, Llop‐Guevara A et al (2018) A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 10:e9172CrossRefPubMedPubMedCentral

17.

Davy G, Rousselin A, Goardon N et al (2017) Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer. Eur J Hum Genet 25:1147–1154. https://doi.org/10.1038/ejhg.2017.116 CrossRefPubMedPubMedCentral

18.

Oliver AW, Swift S, Lord CJ et al (2009) Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 10:990–996. https://doi.org/10.1038/embor.2009.126 CrossRefPubMedPubMedCentral

19.

Buisson R, Niraj J, Pauty J et al (2014) Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA Synthesis At Blocked Replication Forks. Cell Rep 6:553–564. https://doi.org/10.1016/j.celrep.2014.01.009 CrossRefPubMedPubMedCentral

20.

Park JY, Singh TR, Nassar N et al (2014) Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene 33:4803–4812. https://doi.org/10.1038/onc.2013.421 CrossRefPubMed

21.

Pauty J, Couturier AM, Rodrigue A et al (2017) Cancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motif. Nucleic Acids Res 45:2644–2657. https://doi.org/10.1093/nar/gkx011 CrossRefPubMedPubMedCentral

22.

Lee J, Li N, Rowley S et al (2018) Molecular analysis of PALB2 associated breast cancers. J Pathol 245:53–60. https://doi.org/10.1111/peps.12055 CrossRefPubMed

23.

Buisson R, Masson J-Y (2012) PALB2 self-interaction controls homologous recombination. Nucleic Acids Res 40:10312–10323. https://doi.org/10.1093/nar/gks807 CrossRefPubMedPubMedCentral

24.

Naipal KAT, Verkaik NS, Ameziane N et al (2014) Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 20:4816–4826. https://doi.org/10.1158/1078-0432.CCR-14-0571 CrossRefPubMed

25.

Buisson R, Dion-Côté A-M, Coulombe Y et al (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17:1247–1254. https://doi.org/10.1038/nsmb.1915 CrossRefPubMedPubMedCentral

26.

Southey MC, Winship I, Nguyen-Dumont T (2016) PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract 14:9. https://doi.org/10.1186/s13053-016-0049-2 CrossRefPubMedPubMedCentral

27.

Nepomuceno TC, De Gregoriis G, de Oliveira FMB et al (2017) The role of PALB2 in the DNA Damage response and cancer predisposition. Int J Mol Sci. https://doi.org/10.3390/ijms18091886 CrossRefPubMedPubMedCentral

28.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–423. https://doi.org/10.1038/gim.2015.30 CrossRefPubMedPubMedCentral

Title: Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T
Authors: Laura Duran-Lozano
Gemma Montalban
Sandra Bonache
Alejandro Moles-Fernández
Anna Tenés
Marta Castroviejo-Bermejo
Estela Carrasco
Adrià López-Fernández
Sara Torres-Esquius
Neus Gadea
Neda Stjepanovic
Judith Balmaña
Sara Gutiérrez-Enríquez
Orland Diez
Publication date: 01-04-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-05094-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours

Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study

Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer